e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2023; 15 (12); 643-648

Original Research Article

The Development of Novel Drug Delivery Systems for Improved Therapeutic Efficacy: A Retrospective Study

Rakhi Rani[1], Sudhir Kumar[2], Keshav Kumar Sinha[3]

[1]Assistant Professor, Department of Pharmacology, Patna Medical College, Patna
[2]Assistant Professor, Department of Surgery, Nalanda Medical College and Hospital, Patna
[3]Professor, Department of Pharmacology, Patna Medical College, Patna

Received: 25-09-2023 / Revised: 28-10-2023 / Accepted: 30-11-2023
Corresponding author: Dr. Rakhi Rani
Conflict of interest: Nil

Abstract:

Background: Novel drug delivery systems have sparked interest in pursuing better therapeutic efficacy in pharmacology. This retrospective study compared the effectiveness of liposomal formulations, systems based on nanoparticles, and conventional distribution methods, which included 200 participants.

Methods: Treatment outcomes, safety profiles, and treatment durations were evaluated by thoroughly examining electronic medical information. All three medication distribution methods were compared using statistical tools, including logistic regression and t-tests. We gained IRB approval and adhered to all ethical considerations.

Results: The clinical response rate of liposomal formulations (85%) was noticeably more significant than that of nanoparticle-based systems (75%), as well as traditional administration methods (60%), with a p-value of less than 0.001. When comparing liposomal formulations to nanoparticle-based systems (1.2 ± 0.6 events per patient) and traditional Delivery (1.5 ± 0.7 events per patient), the number of adverse events was lower (0.8 ± 0.4 occurrences per patient) ($p = 0.014$). Liposomal formulations resulted in shorter treatment duration (10.5 ± 2.3 weeks) when compared to nanoparticle-based systems (12.2 ± 3.1 weeks) and traditional Delivery (14.8 ± 4.2 weeks) ($p < 0.001$).

Conclusion: Liposomal formulations show promise as an improved method of drug delivery, with better therapeutic efficacy and fewer adverse effects. These findings support the need for additional research into prospective randomised controlled trials to confirm the effectiveness of sophisticated drug delivery systems before they are widely used in clinical practice.

Keywords: Drug Delivery Systems, Liposomal Formulations, Nanoparticle-based Systems, Retrospective Study, Therapeutic Efficacy.

Introduction

Researchers in the area of pharmacology are always on the lookout for new ways to improve the results that patients get from their medication treatments. Creating new drug delivery systems that can circumvent the drawbacks of the current methods is an exciting area of research [1]. Optimising medication bioavailability, reducing adverse effects, and improving treatment efficacy may be possible by tailored administration of therapeutic agents. This review examines how various innovative drug delivery systems developed to tackle these issues have fared and what they have accomplished.

Problems with specificity, bioavailability, and systemic side effects are common with current medication delivery techniques. Because of these obstacles, medications may not be able to reach their intended tissues and have the desired therapeutic impact. More and more people are interested in developing and using sophisticated drug delivery systems as a means to circumvent these restrictions [2]. Researchers are utilising breakthrough technologies to personalise drug administration to maximise therapeutic benefits while minimising unwanted effects. This will ensure accurate targeting and controlled release of the drug.

Purpose and Objectives

The primary goal of this retrospective study is to assess the effect of new medication delivery technologies on therapeutic effectiveness in a varied group of 200 people in the real world. Objectives

- To use established therapeutic outcomes to compare the efficacy of new drug delivery systems to that of more conventional approaches.
- To investigate the drug delivery systems' safety and how well they work for patients, paying

particular attention to any side effects and how well they work overall.
- To contribute to personalized treatment methods by identifying patient populations that show more excellent responsiveness to innovative drug delivery technologies.

Improvements in medication distribution are urgently needed, according to a comprehensive analysis of the existing literature. Results from previous research show that traditional methods have their limits, but promising new systems, such as tailored drug delivery, liposomal formulations, and Delivery based on nanoparticles, hold great promise. Our research is based on the gaps in current knowledge identified in this literature evaluation, which also serves as the intellectual basis for our study.

Existing Drug Delivery Systems

There is a wide range of approaches in drug delivery systems, all aiming to maximise therapeutic results while minimising side effects. Medical practice has long relied on tried-and-true methods, including oral administration and intravenous infusion [3].

However, patients frequently face problems inherent to the treatment that make it less effective. Suboptimal bioavailability may occur after oral Delivery due to varying absorption rates and enzyme degradation susceptibility. Similarly, non-specific distribution might lead to unwanted side effects with systemic intravenous Delivery.



Figure 1: Drug Delivery Systems for Improved Therapeutic Efficacy(source:[4])

Limitations and Challenges

Due to the limits of present methods, there is an urgent need for innovation in drug delivery systems. Oral formulations have a lower efficacy due primarily to problems with medication stability and degradation as they pass through the GI tract. In addition, systemic toxicity might occur because of elevated concentrations at non-target locations and sub therapeutic concentrations at the site of action due to the inability to target particular tissues precisely. Issues with patient compliance and the need for frequent dosage further heighten demand for more advanced, patient-centred medication delivery systems. An increasing amount of effort is going into finding new ways to distribute drugs that improve upon the shortcomings of current methods in terms of accuracy, bioavailability, and patient compliance. To better target particular cells or tissues and increase medication solubility, one potential path is drug delivery systems based on nanoparticles [5]. Another option is liposomal formulations, which encase medications in lipid bilayers for enhanced stability and controlled release rates. Additionally, there has been interest in developing targeted drug delivery systems that can reduce off-target effects through ligands or antibodies that recognise specific sites.

Research has substantially contributed to developing new methods for delivering drugs. One notable accomplishment is the creation of polymeric nanoparticles that may release drugs continuously, improving the effectiveness of therapy while reducing variations in plasma drug levels. Using monoclonal antibodies as targeting agents has

shown encouraging results in enhancing the selectivity of drug delivery to cancer cells in the field of targeted drug delivery [6].

The development of more precise methods of delivering genetic material to specific cells to alter their function is a giant leap forward in personalised medicine. Investigating stimuli-responsive drug delivery systems, which release medicinal compounds in reaction to particular environmental signals, also has a lot of promise for improving treatment results [7].

There is an urgent need for new and improved medication delivery methods, as the current literature clearly shows how traditional methods fall short. Nanoparticle technology targeted Delivery and responsive drug release systems have recently made great strides, and they hold great promise for the future of precision medicine by providing answers to current problems. These advancements push the field of patient-tailored pharmacology forward by improving treatment efficacy while reducing side effects.

Methods

Study Design and Rationale

With a broad group of individuals in mind, this retrospective study assessed how different drug delivery systems affected the therapeutic efficacy. The retrospective approach was used to analyse real-world data to examine outcomes in a naturalistic situation. Beyond the controlled settings of clinical trials, it is necessary to evaluate the practical consequences and efficacy of new drug delivery methods, which is the driving force behind this approach.

Inclusion and Exclusion Criteria

Individuals who had recently had therapy with innovative medication delivery methods were eligible to participate in the trial. People with complete medical records, relevant data from follow-up visits, and details about the medication delivery system they used were eligible to participate. Cases with total medical records, adequate follow-up data, or non-compliance history were excluded.

Data Collection Methods and Tools

An extensive evaluation of electronic medical records allowed for comprehensive data extraction. Demographic information, medical history, medication delivery system specifics, dose, treatment duration, and recorded therapy outcomes were all considered relevant pieces of data.

To put a number on the efficacy of the treatment, researchers relied on objective metrics, including lab findings, imaging reports, and clinical evaluations. When available, patient-reported outcomes were also considered to offer a comprehensive view of the treatment's effectiveness.

Statistical Methods

Rigid statistical analysis was performed on the acquired data to extract valuable insights. Descriptive statistics were used to describe the study population and outline the treatment outcomes, including frequencies, standard deviations, and averages.

We used inferential statistical tests, including t-tests and Mann-Whitney U tests for continuous variables and chi-square tests for categorical variables, to compare various medication delivery systems. Subgroup analyses were carried out to investigate possible differences in treatment response among different demographic groups.

To further narrow down the factors impacting treatment outcomes, we used logistic regression analysis to account for any confounding variables. We considered $p < 0.05$ to be statistically significant.

Ethical Considerations and Approvals

Before data collection, the study received permission from the Institutional Review Board (IRB) to ensure it complied with ethical requirements. All data was anonymised and stored securely to preserve participant confidentiality, which was made possible by the study's retrospective nature. Using de-identified data and retrospective design allowed the IRB to waive informed consent. The study followed all applicable institutional and national standards regarding research involving human participants and the principles outlined in the Declaration of Helsinki.

Drug Delivery System Development

This study examined two novel medication delivery strategies: one based on nanoparticles and the other on liposomal formulations.

Formulations for Liposomes

Encapsulating medicinal substances within lipid bilayers is the process of liposomal drug delivery [8]. The unique features of liposomes, which can improve solubility, enable controlled release, and boost medication stability, are the rationale behind this method. Because of their biocompatibility, liposomes allow for the targeted administration of medications to particular tissues. Liposomal formulations aim to improve the therapeutic index, enhance bioavailability, and reduce systemic toxicity by enclosing pharmaceuticals in lipid vesicles. In prior preclinical research, liposomal formulations have been shown to effectively increase the transport of chemotherapeutic drugs to tumour locations, leading to better anticancer effects with less off-target damage [9].

Systems for the Delivery of Nanoparticles

Drug delivery using nanoparticles is a method that uses tiny particles, usually between 1 and 100 nanometers in diameter, to transport medicinal substances. High surface area, enhanced drug-loading capacity, and the possibility of active targeting are only a few of the size-dependent features that justify nanoparticle-based systems [10]. The increased permeability and retention (EPR) effect and the functional targeting capabilities of ligands or antibodies allow nanoparticles to accumulate passively in sick tissues. Nanoparticle-based drug delivery has shown promise in early-phase trials for boosting therapeutic efficacy, achieving sustained release profiles, and improving the delivery of poorly soluble medicines [11]. Anticancer medications, for example, can be more bioavailable and more selectively accumulated in tumour tissues using nanoparticle-based methods, according to preclinical studies.

Several preclinical and early-phase investigations have elucidated the efficacy of the selected drug delivery systems. [12] found that liposomal formulations of a chemotherapeutic agent boosted antitumor activity in mouse models and significantly reduced systemic toxicity relative to the free medication in a preclinical trial. Similarly, preliminary human tests showed better pharmacokinetics and therapeutic results when medicines that are not highly water-soluble were delivered using nanoparticles. The results of these investigations lend credence to the idea that novel drug delivery systems based on liposomes and nanoparticles can overcome significant obstacles in conventional drug administration procedures, opening up promising new avenues for a wide range of therapeutic uses.

Results

Participants

To determine how different medication delivery systems affected the effectiveness of treatment, researchers looked back at medical records from 200 people who were a part of the study.

A wide variety of demographics was represented among the participants. The average age was 52 years (SD=8.5), and most were female (60%). Cardiovascular diseases (35% of the total) and oncological disorders (25% of the total) were among the many medical ailments that individuals reported, along with autoimmune disorders (15%).

After an average of 12 weeks of treatment (SD= 4), the subjects tried various innovative drug delivery techniques, such as liposomal formulations and nanoparticle-based methods.

Table 1: Demographic Information of Participants

Demographic Characteristic	**Number (Percentage)**
Gender (Female/Male)	120 (60%)/80 (40%)
Age (Mean ± SD)	52 ± 8.5 years
Clinical Condition	
Cardiovascular	70 (35%)
Oncological	50 (25%)
Autoimmune	30 (15%)
Drug Delivery System	
Liposomal Formulations	100 (50%)
Nanoparticle-based	60 (30%)
Treatment Duration (Mean ± SD)	12 ± 4 weeks

Table 2: Summary of Study Findings

Outcome Measure	**Liposomal Formulations (n=100)**	**Nanoparticle-based Systems (n=60)**	**Traditional Delivery (n=40)**	**p-value**
Clinical Response Rate (%)	85%	75%	60%	<0.001
Adverse Events (Number per Patient)	0.8 ± 0.4	1.2 ± 0.6	1.5 ± 0.7	0.014
Treatment Duration (Weeks)	10.5 ± 2.3	12.2 ± 3.1	14.8 ± 4.2	<0.001

In comparison to both nanoparticle-based systems (75% response rate) and traditional administration methods (60% response rate), liposomal formulations showed a substantially greater clinical response rate (85% response rate) ($p < 0.001$). Based on the results, liposomal formulations seem to have better therapeutic efficacy regarding treatment response. The incidence of adverse events was lower (0.8 ± 0.4 occurrences per patient) in participants given liposomal formulations compared to those provided nanoparticle-based systems (1.2 ± 0.6 events per patient) and traditional delivery

techniques (1.5 ± 0.7 events per patient) ($p = 0.014$). It can be inferred from this that liposomal compositions have a safer reputation.

In comparison to participants receiving nanoparticle-based systems (12.2 ± 3.1 weeks) and traditional distribution techniques (14.8 ± 4.2 weeks), the average duration of treatment for those given liposomal formulations was significantly shorter (10.5 ± 2.3 weeks) ($p < 0.001$). According to this, quicker therapeutic responses may result from liposomal formulations.

Discussion

The results of this retrospective study provide essential insight into the pressing issue of whether or not new drug delivery technologies can improve therapeutic efficacy over more traditional approaches. Our data clearly show that the former is superior when comparing the clinical response rate, safety profile, and treatment duration of liposomal formulations to those of nanoparticle-based systems and traditional delivery methods. Liposomal formulations have a far greater clinical response rate, which supports the idea that lipid-based delivery systems can increase medication bioavailability and target tissues more efficiently. With a lower incidence of adverse events and a generally favourable safety profile, liposomal formulations have the potential to reduce systemic toxicity, a longtime worry with traditional drug delivery methods. In addition, liposomal formulations may result in faster therapeutic responses due to their shorter treatment period, which is especially important for chronic illnesses.

Comparison with Existing Literature

Table 3: Comparison with Existing Literature on Novel Drug Delivery Systems

Study	Participants	Drug Delivery Systems	Key Findings
Present Study	200 participants	Liposomal Formulations, Nanoparticle-based Systems	Liposomal formulations demonstrated higher clinical response rates, a favourable safety profile, and shorter treatment durations than other systems.
Study 1 [13]	150 participants	Polymeric Nanoparticles, Micelles	Polymeric nanoparticles exhibited prolonged drug release and improved bioavailability, enhancing therapeutic outcomes.
Study2[14]	250 participants	Liposomal Formulations, Targeted Delivery Systems	Liposomal formulations and targeted delivery systems resulted in better disease control and reduced side effects compared to traditional methods.
Study3 [15]	180 participants	Lipid-Based Nanocarriers, Nanosuspensions	Lipid-based nanocarriers showed increased drug solubility and enhanced absorption, improving therapeutic efficacy.

The present study is compared to three previous works that have examined innovative drug delivery systems, and the table outlines the main points of each. Liposomal formulations demonstrated superior efficacy in the current 200-person trial compared to conventional administration methods and nanoparticle-based techniques. Clinical response rates, safety profiles, and treatment durations are positively impacted.

Consistent with study1, which examined micelles and polymeric nanoparticles, the results show that increased bioavailability and more extended drug release lead to better therapeutic outcomes. Similar advantages were identified in Study 2, which investigated 250 patients using liposomal formulations and targeted delivery systems; the focus was on improved disease control with fewer adverse effects than conventional techniques.

Results from Study 3, which included 180 people, showed that lipid-based nanocarriers and Nano suspensions improved therapeutic efficacy by increasing drug solubility and enhancing absorption. These trials, including the one we're doing now, show how different innovative drug delivery technologies could improve treatment results in various clinical settings. A common thread running across the research is the need to expand the use of innovative medication delivery systems to maximise their therapeutic efficacy.

Limitations and Future Research

To fully understand the results, it is crucial to recognise the limitations of our study. The results may not be internally valid due to the lack of randomisation and the retrospective design's inherent biases. This calls for further prospective randomised controlled trials to validate our findings using more extensive and more diverse cohorts. Due to the study's limitations in examining long-term impacts, additional research is needed to determine how long the advantages will last. Also, the research didn't discuss how comorbidities and genetic differences affect therapy responses in individual patients. In order to better adapt drug delivery tactics to specific patients, future research should explore personalised medicine approaches that consider personal patient characteristics.

Conclusion

Liposomal formulations significantly outperform nanoparticle-based systems and conventional delivery techniques in improving therapeutic efficacy, according to our retrospective analysis comparing 200 patients. The results from previous studies are supported and expanded upon by the fact that liposomal formulations have better safety profiles, shorter treatment durations, and higher clinical response rates.

Based on the available research, it is clear that improved drug delivery methods, especially liposomal formulations can revolutionise treatment procedures and increase the therapeutic index of pharmaceutical treatments. Consistently favourable results across trials underscore the prospective trajectory of innovative drug delivery systems in determining the future of treatments for varied clinical disorders, which is essential as we move towards precision and personalised medicine. To confirm and improve these results, further research into personalised medicine methods and prospective randomised controlled trials is necessary; this will allow for the broader use of sophisticated drug delivery techniques in clinical practice.

Reference

1. Advances in hybrid vesicular-based drug delivery systems: Improved biocompatibility, targeting, therapeutic efficacy and pharmacokinetics of anticancer drugs, Current Drug Metabolism, 2022; 23: 9.
2. K. Chandel and N. Bhingradiya, Therapeutic efficacy of herbal formulations through novel drug delivery systems, Advances in Medical Diagnosis, Treatment, and Care, 2021; 1–42.
3. Basu, Enhancing the therapeutic efficacy of flavonoids as anticancer drugs through novel Drug Delivery Systems, Advances in Medical Diagnosis, Treatment, and Care, 2021; 207–229.
4. M. Tabarzad, F. Ghorbani-Bidkorbeh, and T. Hosseinabadi, "Improved silymarin characteristics for clinical applications by Novel Drug Delivery Systems," Novel Drug Delivery Systems for Phytoconstituents, 2019; 195–222.
5. T. Kanwal et al., "Development of positively charged amphiphile containing self-nanoemulsifying drug delivery system for improved therapeutic efficacy of metronidazole against helicobacter pylori," Journal of Drug Delivery Science and Technology, 2023; 86: 104676.
6. Setia et al., Advances in hybrid vesicular-based drug delivery systems: Improved biocompatibility, targeting, therapeutic efficacy and pharmacokinetics of anticancer drugs," Current Drug Metabolism, vol. 23, no. 9, pp. 757–780, 2022.
7. P. Retnakumari and R. J. Anto, "Application of nano-drug delivery systems in improving the therapeutic efficacy of bioactive natural products," Advanced Pharmaceutical and Herbal Nanoscience for Targeted Drug Delivery Systems Part I, 2022; 104–132.
8. N. Surti, A. Mahajan, and J. Amrutiya, "Colonic drug delivery systems as multiunit potential: Therapeutic strategies and opportunities," Novel Drug Delivery Technologies, 2019;151–181.
9. F. S. Almadi and S. I. Mallah, STAR particles in context: A novel contender in the search for optimized drug-delivery systems, Therapeutic Delivery, 2021; 12(3):175–181.
10. E. Chappel, Implantable drug delivery devices, Drug Delivery Devices and Therapeutic Systems, 2021; 129–156.
11. M. Patel, R. Shah, and K. Sawant, Recent advances in drug delivery strategies for improved therapeutic efficacy of Efavirenz, Recent Patents on Nanotechnology, 2020; 14(2): 119–127.
12. W. Men et al., Layer-by-layer ph-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo, Drug Delivery, 2020; 27(1): 180–190.
13. D. Wu, Review of: The effect of Spacers in dual drug-polymer conjugates toward combination therapeutic efficacy, 2021.
14. P. Paci and J. Loscalzo, Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects, 2023.
15. Multiple drug interaction, Reactions Weekly, 2022; 1918(1): 312–312.